This is in addition to having already received the FDA’s clearance to market the company’s patented Microwave coagulation/ablation system for surgical applications.
The system and single patient use devices enable surgeons and interventional radiologists to treat soft tissue problems, such as tumors, using microwave thermal ablation. The clearance sets the stage for rapid expansion of the Company’s product portfolio and indications for use through additional U.S. FDA clearances. The Company’s proprietary technology focuses on the development of minimally invasive devices in wide ranges of size, shape and flexibility intended to meet clinicians’ requirements for treatment of tumors in bone, liver, lung and other locations.
According to the company, the Microwave coagulation/ablation system overcomes limitations of existing microwave and radiofrequency thermal ablation technologies, the standard of treatment for cancerous tumor patients who are not candidates for resection surgery.
For these patients, microwave ablation can be adjunctive or a replacement for the curative or palliative therapies of standard therapies, such as chemotherapy or radiation. It can be an option for patients where other thermal modalities are not possible due to tumor size, location or patient condition, the company said.